Oncotype DX Genomic Prostate Score (GPS) is the only assay that addresses the unique challenges associated with Active Surveillance treatment decisions.

Prolaris does not.

Not all prostate cancer assays are the same. The GPS assay drives immediate and actionable decisions for early-stage prostate cancer, while Prolaris falls short.

For your 3+3 and 3+4 GS patients, choose the right assay to inform Active Surveillance or treatment.

Genomic Prostate Score (GPS) Prolaris
Addresses unique features of prostate cancer, including heterogeneity and multifocality1,2
Genes selected based on their performance in prostate cancer in the biopsy setting1,2
Integrates multiple biological pathways critical to prostate cancer aggressiveness1,2
Optimized for small prostate biopsy tissue samples2,3
Extensively validated across large cohorts of GS 3+3 and 3+4 patients, who are eligible for Active Surveillance3-16
Prospective validation data for a clinical endpoint12
Validated as a predictor of adverse pathology (AP)1,13
Validated as a predictor of metastasis after radical prostatectomy (RP)14-17
Validated as a predictor of prostate cancer death after RP14-17
Validated as a predictor of biochemical recurrence (BCR)13,14,17

Oncotype DX Genomic Prostate Score (GPS) Assay
Developed and Validated with genes specific to prostate cancer growth and differentiation


Over 1 million breast, colon, and prostate cancer patients have used an Oncotype DX assay to help guide their treatment decisions


 
REFERENCES
  1. Klein et al. Eur Urol. 2014.
  2. Cuzick et al. Lancet Oncol. 2011.
  3. Knezevic et al. BMC Genomics. 2013.
  4. Badani et al. Urol Pract. 2015.
  5. Lynch et al. Am J Manag Care. 2018.
  6. Albala et al. Rev Urol. 2018.
  7. Dall’Era et al. Urol Pract. 2015.
  8. Bonham et al. USCAP 2016.
  9. Salmasi et al. J Urol. 2018.
  10. Eure et al. Urology. 2017.
  11. Eure et al. AUA 2017.
  12. Eggener et al. Urology. 2019.
  13. Cullen et al. Eur Urol. 2015.
  14. Van Den Eeden et al. Eur Urol. 2017.
  15. Cuzick et al. Br J Cancer. 2015.
  16. Cuzick et al. Br J Cancer. 2012.
  17. Bishoff et al. J Urology. 2014.
 
† Prolaris is a registered trademark of Myriad Genetics, Inc. Please refer to this manufacturer directly for more information.
Contact Us

Order the Test

Use our Physician Portal to securely order and view test results.

Log In Now

Available Now

The Oncotype DX Genomic Prostate Score test predicts
both clinical risk and tumor aggressiveness.

Learn More

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™